Guide · updated 2026-08-24

Compounded vs brand-name, with the trade stated

Last verified 2026-08-24 · methodology · conflict-of-interest disclosure · dataset: open JSON

The trade in one sentence: brand buys FDA review of the finished product and trial evidence generated on the exact item you inject, at verified cash prices of $299–$449 conditional (Zepbound vials) and $349 ongoing (Wegovy); compounded buys the same molecule from a licensed pharmacy on a patient-specific prescription at $69–$97/mo verified floors — lawful post-shortage for a documented clinical need, and not FDA-approved, which is the whole trade. Last verified 2026-08-24.

Side by side

	Brand (Wegovy / Zepbound)	Compounded (sema / tirz)
FDA approval of the product	Yes	No — not FDA-reviewed
Evidence	STEP/SURMOUNT tested this product	Molecule-level; trial file doesn’t transfer
Form	Prefilled pens; manufacturer vials	Multi-dose vial + syringe; concentration varies by pharmacy
Legal basis	NDA-approved product	§503A patient-specific prescription, documented clinical need
Cash price on file	$349 ongoing, $199 first fill (NovoCare) / $299–$449 conditional (LillyDirect) — verified 2026-08-25	$69 / $97 — verified floors
Where it wins	Coverage, device simplicity, approval status	Self-pay budgets, flat-dose pricing, access

Who should pick brand

Anyone with coverage or savings-card eligibility — a copay beats every cash number on this site. Anyone for whom “FDA-approved” is a requirement rather than a preference. Anyone who wants the pen instead of vial-and-syringe mechanics.

Who compounded actually fits

Cash payers priced out of $199–$499/month — the $69 verified floor is the difference between treatment and no treatment for a lot of budgets — provided the pharmacy checks out (the checklist) and the not-approved trade is accepted with open eyes, not buried in footnotes. The 2025 wind-down ended mass 503B compounding; patient-specific 503A compounding for documented need is the lane that remains — details on the legality explainer.

Update log

2026-08-24 — Page created per the Pass-12 audit; sources inline.